Overview
Cancer Cachexia Market size is forecast to reach $2.22 billion by 2024, growing at a CAGR of 4.61 % during the forecast period 2019-2024. Increasing prevalence of cachexia amongst the geriatric population and rising pipeline products for cachexia cancer patients are the factors driving the growth of the market. Increasing R&D investments and growing technological advancements for the treatment of cancer cachexia will further enhance the overall market demand of cancer cachexia during the forecast period.
Key Takeaways
North America dominates the cancer cachexia market owing to presence of large number of drug manufacturers and advancement in novel technology.
The growing population for cancer treatment and pipeline products for the treatment of cancer cachexia which are yet to be in the market is likely to aid in the market growth of cancer cachexia market.
Detailed analysis on the Strength, Weakness and opportunities of the prominent players operating in the market will be provided in the cancer cachexia market report.
Stringent regulatory requirements and delay in the treatment due to unawareness will create hurdles for the cancer cachexia market.
Therapeutics - Segment Analysis
Progestogens held the largest
share in the cancer cachexia market in 2018 and will grow at a CAGR of 5.2%
during the forecast period 2019-2024. This is mainly owing to the factors such
as the effective and safest option for the palliative treatment of cancer
cachexia which will play a significant role in the progestogens segment to
maintain its market position. Current
therapies focus on palliation of symptoms and the reduction of distress of
patients and families rather than cure. However, Combination Therapies is
estimated to be the fastest growing segment owing to its use of novel pharmaceutical
agents such as Megestrol acetate, medroxyprogesterone, ghrelin, omega-3-fatty
acid among others. These agents are reported to have improved survival rates as
well as quality of life.
Mechanism of Action - Segment Analysis
Weight Loss Stabilizers holds a
major share in the cancer cachexia market in 2018 and is estimated to grow at a
CAGR of 4.5% during the forecast period 2019-2024. Cystic fibrosis, tissue
wasting, wasting syndrome, and inflammatory cytokins are the major problems
that occur in cancer cachexia. Anorexia nervosa is an eating disorder
characterized by weight loss. Countering weight loss in cancer cachexia is
vital in improving the quality of life in the patients. Cancer cachexia is
characterized by the poor tolerance of antitumour treatments, notably to
chemotherapy and radiotherapy, unhindered loss of muscles which may even lead
to death. Approximately half of all cancer patients experience cachexia, with a
prevalence of up to 86% in the last 1-2 week of life, and 45% of patients lose
more than 10% of their original body weight during disease advancement. Death usually occurs when there is 30%
weight loss. Therefore doctors are recommending the use of weight loss
stabilizers to prevent cancer cachexia among the patients.
Geography - Segment Analysis
North America dominated the cancer cachexia market with a
share of more than 45%, followed by Europe. Presence of a large number of drug
manufacturers and advancing paradigm of care for cancer patients is supporting
the growth in this region. Advancements in novel technology for the treatment
of cancer cachexia and strong product pipeline for wasting syndrome has also
helped in the growth of the cancer cachexia market in the region.
However, Asia-Pacific is estimated to grow at a higher
CAGR during the forecast period. This is so because of the growing geriatric
populations in countries such as Japan, China and increasing awareness among
people and healthcare professionals about cancer supportive care. The high prevalence and incidence of
the cancer will lead to the expansion of the global cancer cachexia market in
this region.
Drivers – Cancer Cachexia Market
Rising prevalence for novel therapies
The lack of approved drugs for cachexia treatment in patients and monotherapy administration with progestogens and corticosteroids has led cancer patients and doctors to opt for alternative therapeutic approaches. As a result, the industry is gaining traction through a combination of multiple medical and nutritional therapeutic interventions. These therapies provide better profiles of safety and efficacy. Companies ' increasing R&D and the availability of new drugs for cancer cachexia treatment facilitate their adoption among patients. It is predicted that this innovation will have a positive impact on overall market growth.
Rising pipeline products for the cachexia cancer and Increasing geriatric population
The increasing
prevalence of cachexia, especially among the geriatric population, such as
North America, Europe, and Japan, is the main factor behind the significant
growth of the market for cancer cachexia. The presence of pipeline drugs in
phase 3 clinical trial, which is expected to be rolled out in the market over
the next 2-3 years, is also expected to drive the market for cancer cachexia.
Challenges – Cancer Cachexia Market
Stringent Regulatory requirements
Manufacturers of cancer cachexia drugs are discouraged
from investing in the market because of the strict regulatory requirements and
the long FDA approval procedure, which may impede the long-term growth of this
market. The medications
for cancer have therapeutic effects as well as related side effects. It is therefore important to monitor
closely that the adverse effects do not surpass the therapeutic effects.
Because of this, the regulations
are strict and can be a challenge for the manufacturers at times. Hence, the stringent regulatory
requirements are restraining the market for cancer cachexia drugs.
Cancer cachexia market outlook
Product launches, acquisitions and R&D activities are
key strategies adopted by players in the cancer cachexia market. In 2018, the cancer
cachexia market share is fragmented by the top ten players. Cancer Cachexia top
10 Companies are Eli Lilly and Co, Merck
& Co. Inc., Novartis AG, Bristol-Myers Squibb Co., AEterna Zentaris Inc., Alder
BioPharmaceuticals Inc., Boston Biomedical, Boehringer Ingelheim GmbH, , among others.